Maryland Technology Development Corporation (TEDCO), recently announced that its Rural and Underserved Business Recovery from Impact of COVID-19 (RUBRIC) program awarded grants to 45 Maryland companies. Leading as Maryland’s Economic engine for technology companies, TEDCO focused awards on companies that were considered socially and economically disadvantaged as well as those in the rural areas. According to TEDCO’s website “The funds are administered by TEDCO to early-stage companies that are impacted by the current crisis and are in need of bridge funding to survive and prosper as the downturn and COVID-19 crisis subsides. The funding is focused on companies that have the highest barriers to traditional financing but are still expected to scale to the next phase of fundraising.” OS Therapies, Inc., a Dorchester county business was one of the 45 Maryland companies to be awarded.
Located in the Eastern Shore Innovation Center, OS Therapies, Inc. (OST), is a clinical stage therapeutic company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other deadly cancers in children and adults. OS Therapies has two platform technologies being developed for therapies to treat and cure Osteosarcoma (OS) and other deadly cancers in both children and adults including ovarian, esophageal, endometrial and lung cancers.
There is a significant need for new and more effective treatments in cancers of the bone due to specific challenges associated with treating these types of cancers, like location, rarity, gene mutations, and high recurrence rates. With a goal to increase overall survival and prevent recurrence, OST has created the first potential treatment plan for OS in nearly 30 years. Their solution is OST-HER2, an immunotherapy treatment, also known as a preventative cancer therapeutic T Cell “Vaccine”. The OST-HER2 platform technology has already been administered into approximately 450 healthy volunteers in successful and completed clinical trials. Later next month, OS Therapies will initiate a potentially pivotal Phase IIB clinical trial intended to prevent metastasis and improve survival of Osteosarcoma.
Also expected in the upcoming weeks, OS Therapies will receive the Rare Pediatric Disease Designation (RDD) for OST-HER2 (OST31-164) for the treatment of Osteosarcoma through the U.S. Food and Drug Administration (FDA). They plan to use their grant money to help fund their early-stage treatment technologies to further their therapeutic research, phased trials, and agency approval processes.
To learn more about OS Therapies, Inc, visit their website by clicking here.
You can also click here to read the announcement of the TEDCO grant awardees.